Izeltabart tapatansine is a monoclonal antibody conjugated commercialized by ImmunoGen, with a leading Phase II program in Gastroesophageal (GE) Junction Carcinomas. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Izeltabart tapatansine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Izeltabart tapatansine is expected to reach an annual total of $72 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Izeltabart tapatansine Overview
Izeltabart tapatansine is under development for the treatment of advanced or metastatic solid tumors including non-squamous non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), gastroesophageal cancer and pancreatic cancer. The drug candidate comprises of a high affinity humanized antibody with YTE mutation conjugated to DM21, with a stable peptide linker. It is administered through intravenous route. The drug candidate acts by targeting ADAM9 expressing tumor cells.
ImmunoGen is a clinical-stage biotechnology company that focuses on the development of novel antibody-drug conjugates (ADCs) that facilitate targeted therapies for the treatment of cancer. Its pipeline product candidates include mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer; IMGN632 for AML, and pivekimab sunirine for blastic plasmacytoid dendritic cell neoplasm (BPDCN); IMGC936, the company’s product candidate for a range of solid tumors; and IMGN151, its next-generation anti-FRa candidate in the preclinical development stage. ImmunoGenorporates its proprietary product development ADC technology to enhance the anticancer activity of monoclonal antibodies. The company has direct operations in the US, Ireland, and the UK. ImmunoGen is headquartered in Waltham, Massachusetts, the US.
The company reported revenues of (US Dollars) US$108.8 million for the fiscal year ended December 2022 (FY2022), an increase of 55.7% over FY2021. The operating loss of the company was US$220.9 million in FY2022, compared to an operating loss of US$125.1 million in FY2021. The net loss of the company was US$222.9 million in FY2022, compared to a net loss of US$139.3 million in FY2021. The company reported revenues of US$49.9 million for the first quarter ended March 2023, an increase of 21.1% over the previous quarter.
For a complete picture of Izeltabart tapatansine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.